Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment ((KISV))
Smoking Cessation

About this trial
This is an interventional treatment trial for Smoking Cessation
Eligibility Criteria
Inclusion Criteria: African American age >18 years interested in quitting smoked >1 cpd for >1 years smoked on >25 days in the past month willing to take 6 months of study medication and complete all visits have a home address and functioning telephone number Exclusion Criteria: Consistent with contraindications for bupropion: use of psychoactive medications history of alcohol or substance abuse within the past year binge drinking (>5 drinks on one occasion) >2 times in the past month history of seizures or head trauma; history of bulimia or anorexia nervosa pregnant (as measured by over the counter pregnancy test kit for women of child-bearing age only) or contemplating pregnancy; breast feeding myocardial infarction in the past 2 months reported use of opiates, cocaine, or stimulants unstable diabetes bupropion is a known inhibitor of the liver enzyme CYP2D6, so those taking drugs known to be higher metabolized by this enzyme (e.g., metoprolol, tamoxifen) will be excluded. use of stop smoking medications (bupropion, varenicline, nicotine replacement, fluoxetine, clonidine, buspirone, or doxepin) in the past 30 days planning to move from the Kansas City area in the next year other smoker in household enrolled in the study.
Sites / Locations
- University of Kansas Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Standard Treatment
Extended Treatment
250 participants will be randomly assigned to the standard treatment arm and receive 7 weeks of bupropion SR following standard dosing guidelines(150 mg once daily for 3 days, then 150mg twice daily for 7 weeks). Participants in this arm will also receive 8 smoking cessation counseling sessions consistent with the Clinical Practice Guidelines.
250 participants will be randomly assigned to the extended treatment arm and receive 24 weeks of bupropion SR following standard dosing guidelines(150 mg once daily for 3 days, then 150mg twice daily for 24 weeks). Participants in this arm will also receive 8 smoking cessation counseling sessions consistent with the Clinical Practice Guidelines.